Peri–operative management of carcinoid syndrome using ketanserin
- 1 June 1986
- journal article
- case report
- Published by Wiley in Anaesthesia
- Vol. 41 (6) , 596-599
- https://doi.org/10.1111/j.1365-2044.1986.tb13050.x
Abstract
This report describes the successful use of ketanserin, a 5-HT2 receptor antagonist, for the acute control of systemic blood pressure in a patient with the carcinoid syndrome, undergoing hepatic artery embolisation. Serial measurements of plasma 5-hydroxyindoles, platelet 5-hydroxytryptamine and plasma catecholamines are also given.Keywords
This publication has 10 references indexed in Scilit:
- STUDIES ON THE MECHANISM OF ACTION OF THE HYPOTENSIVE EFFECT OF KETANSERINClinical and Experimental Pharmacology and Physiology, 1984
- Experience With Ketanserin, A Serotonin (S2) Antagonist, in Longterm Treatment of Essential HypertensionClinical and Experimental Hypertension. Part A: Theory and Practice, 1984
- Alpha 1 antagonistic and antiserotoninergic action during administration of ketanserin.BMJ, 1983
- Role of hepatic arterial embolisation in the carcinoid syndrome.BMJ, 1983
- Circulation, respiration and serotonin levels in carcinoid patients during neurolept anaesthesiaAnaesthesia, 1983
- PROPHYLACTIC USE OF KETANSERIN IN A PATIENT WITH CARCINOID SYNDROMEBritish Journal of Anaesthesia, 1983
- KETANSERIN: A SELECTIVE ANTAGONIST OF 5-HT2 SEROTONINERGIC RECEPTORSThe Lancet, 1983
- MECHANISM OF ACTION OF KETANSERINThe Lancet, 1982
- Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.BMJ, 1982
- Assay of plasma catecholamines by liquid chromatography with electrochemical detectionAnalytical Biochemistry, 1981